Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Chemotherapy. Hormone. University of Rochester School of Medicine and Dentistry, Rochester, NY, United States



Survival: 81.6 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
Hormone
   
Drugs:
Country: United States
   
City/State/Province: Rochester, NY
   
Hospital: University of Rochester School of Medicine and Dentistry
   
Journal: Link
   
Date: 3/2013

Description:
Patients:
This phase 2 study involved 49 previously untreated mantle cell lymphoma patients who. The median patient age was 57.4 years and 78% were male.

Treatment:
Patients were treated with a therapy regimen called hyperCVAD MTX/Ara-C and rituximab. This therapy consists of the chemotherapy agents cyclophosphamide, vincristine, doxorubicin, methotrexate, and cytarabine, the steroid hormone dexamethasone, and the biologic therapy agent rituximab (an antibody against the CD20 protein that helps the immune system attack cancer cells).

Toxicities:
There was one treatment-related death due to infection. Grade 4 leukopenia and neutropenia was reported by 86% and 78% of patients, respectively. Grade 3 flu-like symptoms and grade 3-4 pain were also reported.

Results:
The median overall survival was 81.6 months.

Correspondence: Dr. Steven Bernstein; email: steven_bernstein@urmc.rochester.edu

E-mail to a Friend Email Physician More Information